Handa S, Dogra S, Kumar B
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Dermatolog Treat. 2004 Jan;15(1):55-7. doi: 10.1080/09546630310013450.
Antihistamines are the first line of therapy for chronic idiopathic urticaria (CIU). The present study was designed considering the lack of reports comparing the efficacy and safety of commonly prescribed cetirizine and fexofenadine in the treatment of CIU.
A total of 116 patients, aged 17 to 65 years, with CIU (urticarial wheals for at least two days per week for six consecutive weeks before entry) were enrolled in this randomised double-blind study. Study period was 28 days with patient visits on days 14 and 28 for investigator evaluation of the clinical response. Patient evaluation was on the basis of an analogue scale. Final response to treatment was judged as symptom free, partial improvement, and no improvement.
Ninety-seven patients (52 cetirizine, 45 fexofenadine) completed the study. The response to treatment in both the groups at the end of treatment period was as follows; symptom free [cetirizine 27(51.9%), fexofenadine 2(4.4%)], partial improvement [cetirizine 19(36.5%), fexofenadine 19(42.2%)], no improvement [cetirizine 6(11.5%), fexofenadine 24(53.3%)]. Side effects noted were mild with no significant difference between the two.
Cetirizine seems to have therapeutic advantage over fexofenadine in the treatment of CIU.
抗组胺药是慢性特发性荨麻疹(CIU)的一线治疗药物。本研究旨在填补缺乏关于常用的西替利嗪和非索非那定治疗CIU疗效和安全性比较报告的空白。
本随机双盲研究共纳入116例年龄在17至65岁之间的CIU患者(入选前连续六周每周至少有两天出现风团)。研究期为28天,在第14天和第28天进行患者访视,以便研究者评估临床反应。患者评估基于模拟量表。治疗的最终反应分为无症状、部分改善和无改善。
97例患者(52例使用西替利嗪,45例使用非索非那定)完成了研究。治疗期结束时两组的治疗反应如下:无症状[西替利嗪27例(51.9%),非索非那定2例(4.4%)],部分改善[西替利嗪19例(36.5%),非索非那定19例(42.2%)],无改善[西替利嗪6例(11.5%),非索非那定24例(53.3%)]。观察到的副作用较轻,两组之间无显著差异。
在治疗CIU方面,西替利嗪似乎比非索非那定具有治疗优势。